Arcturus Therapeutics (NASDAQ:ARCT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a strong sell rating to a sell rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings raised Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.25.

Arcturus Therapeutics Trading Down 1.3%

NASDAQ ARCT opened at $5.97 on Friday. Arcturus Therapeutics has a 12-month low of $5.77 and a 12-month high of $24.17. The company has a fifty day simple moving average of $7.17 and a two-hundred day simple moving average of $7.48. The stock has a market cap of $169.67 million, a P/E ratio of -2.12 and a beta of 2.37.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.08. The firm had revenue of $2.06 million for the quarter, compared to analyst estimates of $6.30 million. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%. As a group, sell-side analysts forecast that Arcturus Therapeutics will post -3.99 earnings per share for the current year.

Institutional Trading of Arcturus Therapeutics

Hedge funds have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Arcturus Therapeutics by 206.5% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 240,303 shares of the biotechnology company’s stock valued at $1,473,000 after purchasing an additional 161,910 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its position in Arcturus Therapeutics by 12.9% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock valued at $17,671,000 after buying an additional 262,347 shares during the period. Heartland Advisors Inc. purchased a new position in Arcturus Therapeutics in the first quarter valued at $1,976,000. Castleview Partners LLC purchased a new position in Arcturus Therapeutics in the first quarter valued at $130,000. Finally, Diversify Wealth Management LLC acquired a new position in shares of Arcturus Therapeutics in the first quarter worth about $133,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.